Safety and compatibility of smart device heart rhythm monitoring in patients with cardiovascular implantable electronic devices. (25th June 2019)

• Record Type: Journal Article
• Authors: Abudan, Anas A.; Isath, Ameesh; Ryan, James D.; Henrich, Mark J.; Dugan, Jennifer L.; Attia, Zachi I.; Ladewig, Dorothy J.; Dillon, John J.; Friedman, Paul A.
• Is Part Of: Journal of cardiovascular electrophysiology. Volume 30:Number 9(2019)
• Page Start: 1602
• Page End: 1609
• Publication Date: 2019-06-25
• Subjects: AliveCor -- electrocardiogram -- ICD -- Kardia -- pacemaker -- safety; Blood vessels -- Physiology -- Periodicals; Electrophysiology -- Periodicals; Heart -- Physiology -- Periodicals; 612.1
• DOI: 10.1111/jce.14024
• Languages: English
• ISSNs: 1045-3873

Abstract

Abstract: Introduction: Emerging medical technology has allowed for monitoring of heart rhythm abnormalities using smartphone compatible devices. The safety and utility of such devices have not been established in patients with cardiac implantable electronic devices (CIEDs). We sought to assess the safety and compatibility of the Food and Drug Administration‐approved AliveCor Kardia device in patients with CIEDs. Methods and Results: We prospectively recruited patients with CIED for a Kardia recording during their routine device interrogation. A recording was obtained in paced and nonpaced states. Adverse clinical events were noted at the time of recording. Electrograms (EGMs) from the cardiac device were obtained at the time of recording to assess for any electromagnetic interference (EMI) introduced by Kardia. Recordings were analyzed for quality and given a score of 3 (interpretable rhythm, no noise), 2 (interpretable rhythm, significant noise) or 1 (uninterpretable). A total of 251 patients were recruited (59% with a pacemaker and 41% with ICD). There were no adverse clinical events noted at the time of recording and no changes to CIED settings. Review of all EGMs revealed no EMI introduced by Kardia. Recordings were correctly interpreted in 90% of paced recordings (183 had a score of 3, 43 of 2, and 25 of 1) and 94.7% of nonpaced recordings (147 of 3, 15 of 2, and 9 of 1). Conclusion: The AliveCor Kardia device has an excellent safety profile when used in conjunction with most CIEDs. The quality of recordings was preserved in this population. The device, therefore, can be considered for heart rhythm monitoring in patients with CIEDs.